BioNTech Q2 2024 GAAP EPS EUR(3.36) Misses EUR(1.89) Estimate, Sales EUR128.700M Miss EUR157.008M Estimate
Portfolio Pulse from Benzinga Newsdesk
BioNTech reported its Q2 2024 financial results, missing both earnings and sales estimates. The company posted a GAAP EPS of EUR(3.36), which was below the expected EUR(1.89). Sales were EUR128.700M, falling short of the EUR157.008M estimate.
August 05, 2024 | 10:01 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
BioNTech's Q2 2024 financial results missed both earnings and sales estimates. The company reported a GAAP EPS of EUR(3.36), significantly below the expected EUR(1.89), and sales of EUR128.700M, which also missed the EUR157.008M estimate.
The significant miss on both earnings and sales estimates is likely to negatively impact BioNTech's stock price in the short term. Investors typically react unfavorably to such financial underperformance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100